Stanford Scientists Regrow Lost Knee Cartilage by Blocking a Single 'Aging Enzyme' - No Stem Cells Needed

For decades, the textbook said worn-out joint cartilage doesn’t grow back. A new study from Stanford Medicine, published in Science on June 12, 2026, makes a hopeful case for the opposite: aging joints haven’t lost the ability to heal - that ability is being actively held down by a single enzyme. Block that enzyme, and cartilage can regenerate. The researchers showed it in aged mice, in injured mice, and - encouragingly - in human cartilage tissue.

Here is what they found, how it works, why it matters for one of the most common conditions of aging, and the honest limits of what’s been shown so far.

At a glance

The target: an aging-related enzyme called 15-PGDH, which the team nicknames a “gerozyme” because it builds up with age
The result: blocking it regrew lost cartilage in aged mice and prevented arthritis after injury
The good kind: the new tissue was hyaline cartilage - smooth and load-bearing, not scar-like fibrocartilage
How: by rejuvenating the joint’s existing cells - no stem cells required
Human head start: an oral 15-PGDH inhibitor is already in human trials (for muscle aging) and has cleared Phase 1 safety
Published in: Science, June 12, 2026 (DOI 10.1126/science.adx6649)

The Idea: Aging Isn’t Lost Capacity - It’s Active Suppression

The study comes from the labs of Helen M. Blau, PhD, and Nidhi Bhutani, PhD, at Stanford (with collaborators at Sanford Burnham Prebys). Their central insight is that a protein called 15-hydroxy prostaglandin dehydrogenase (15-PGDH) rises with age and suppresses tissue repair. Because it accumulates as we get older, the team describes it as a “gerozyme” - an enzyme of aging.

The mechanism is elegant. Blocking 15-PGDH raises levels of a signaling molecule called prostaglandin E2 (PGE2), which prompts the joint’s existing cartilage cells (chondrocytes) to shift their gene activity back toward a younger, regenerative state. In other words, the repair machinery was there all along - the enzyme was keeping it switched off.

What Happened in the Experiments

Model	What was done	Result
Aged mice	Given a 15-PGDH inhibitor	Restored lost cartilage thickness across the joint; regrown tissue was functional hyaline cartilage
Injured mice (ACL-type)	Inhibitor twice weekly for 4 weeks after injury	Far less likely to develop osteoarthritis; untreated mice developed it within 4 weeks
Human tissue (ex-vivo)	Samples from knee-replacement surgery, treated 1 week	Fewer degrading cells, lower cartilage-breakdown gene activity, and tissue began generating new cartilage

“This gerozyme inhibitor causes a dramatic regeneration of cartilage beyond that reported in response to any other drug or intervention.” - Dr. Nidhi Bhutani

Why This Could Matter So Much

Osteoarthritis is one of the most common conditions of aging, affecting hundreds of millions of people worldwide. Critically, there is no approved drug that changes the course of the disease - current options manage pain or, eventually, replace the joint entirely. A therapy that regrows the actual cartilage would target the root cause rather than the symptoms.

What makes this especially promising is that the path to people may be shorter than usual. An oral 15-PGDH inhibitor is already being tested in human clinical trials for age-related muscle weakness, and according to the team it has passed Phase 1. As Dr. Blau put it: “Phase 1 clinical trials of a 15-PGDH inhibitor for muscle weakness have shown that it is safe and active in healthy volunteers.” A safety record in humans, even for a different use, can meaningfully speed the road to testing it for joints.

The Honest Caveats

Because credibility matters more than hype, here is exactly what has - and hasn’t - been shown:

The cartilage regeneration is in mice. The dramatic regrowth results come from aged and injured mice, not people.
The human data is from tissue, not patients. The encouraging human result used ex-vivo samples removed during knee-replacement surgery - not a living patient’s joint. No full human trial for cartilage regeneration has been done yet.
There are commercial interests. Several authors are inventors on Stanford patents for 15-PGDH inhibition that are licensed to a biotech company (Epirium Bio), and Dr. Blau is a company co-founder with equity. This is disclosed and normal for translational research, but worth knowing.

None of this diminishes the finding - it sets the right expectations. Promising biology still has to clear human trials, and many do not. But the combination of a clear mechanism, strong animal results, a positive human-tissue signal, and an inhibitor already in human safety testing makes this one of the more credible “regrow your cartilage” stories to come along.

The Bottom Line

The headline most people will remember is the simplest one: worn cartilage may not be permanent. By switching off a single enzyme that accumulates with age, Stanford researchers got the joint’s own cells to rebuild the good kind of cartilage - in animals and in human tissue. It’s early, it’s not a treatment yet, and the human joint trials still have to happen. But for one of aging’s most universal aches, the direction of travel just got a lot more hopeful.

Sources

Curated by Jerry Cards - jerrycards.com. We research the week’s most consequential science, health, and tech news so you don’t have to. More at jerrycards.com/news. This article is for information only and is not medical advice.